KMCRIC

Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia.

Hong JM, Shin DH, Lim YA, Lee JS, Joo IS.

Thromb Res.

2013

131(4)

e147-153.

10.1016/j.thromres.2013.01.026.

23477707

http://www.ncbi.nlm.nih.gov/pubmed/23477707

Acute Disease
Alleles
Aryl Hydrocarbon Hydroxylases/genetics
Brain Ischemia/blood
Brain Ischemia/drug therapy*
Brain Ischemia/genetics
Female
Ginkgo biloba/chemistry*
Humans
Male
Middle Aged
Pilot Projects
Plant Extracts/adverse effects
Plant Extracts/therapeutic use*
Platelet Aggregation/drug effects
Platelet Aggregation Inhibitors/adverse effects
Platelet Aggregation Inhibitors/therapeutic use*
Prospective Studies
Ticlopidine/adverse effects
Ticlopidine/analogs & derivatives*
Ticlopidine/therapeutic use*

cerebral ischemia; Ginkgo biloba extract; combination; antiplatelet; thiennopyridine; cytochrome

뇌경색; 은행 추출물; 배합; 항혈소판; 티에노피리딘; 시토크롬

KMCRIC 비평 보기 +

Y

BACKGROUND: Even though clopidogrel is the most used drug for cardiovascular prevention, resistance occurs in significant numbers. Therefore, we evaluated platelet aggregation ability of thienopyridines in relation with various genotypes. METHOD: The study population was randomly assigned with clopidogrel (n=43), ticlopidine (n=41), or ticlopidine plus Gingko Biloba extract (EGb) (n=43). Dosage was maintained as 75mg clopidogrel daily, 250mg ticlopidine twice daily, and 250mg ticlopidine plus 80mg Gingko Biloba extract twice daily. Using multiple electrodes aggregometry, platelet aggregation was measured by activators of adenosine diphosphate (ADP), arachidonic acid (ASP), and thrombin (TRAP) at baseline (T0), 7days (T1), and 90days (T2). Side-effects were analyzed in the 3 groups. Inhibition of platelet aggregation (IPA) was defined as percent decrease at T0 and T1. Non-responsiveness (

영어